What can a pilot congestive heart failure disease management program tell us about likely return on investment?: A case study from a program offered to federal employees

Disease Management

Volumn 8, Issue 6, 2005, Pages 346-360

  Van Vonno, Catherine J ^a   Ozminkowski, Ronald J ^b,h   Smith, Mark W ^c   Thomas, Eileen G ^d   Kelley, Doniece ^e   Goetzel, Ron ^b   Berg, Gregory D ^f   Jain, Susheel K ^g   Walker, David R ^h  

^a Health and Productivity Research ^*

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c Blue Cross and Blue Shield Association   (United States)

^d Internal Reviews   (United States)

^e McKesson   (United States)

^f ACS Group Companies   (United States)

^g ACS State Healthcare Solutions   (United States)

^h MEDSTAT GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMOGRAPHY; EMPLOYEE; EVALUATION RESEARCH; FEMALE; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE COST; HEALTH INSURANCE; HEALTH PROGRAM; HEART DISEASE; HUMAN; INVESTMENT; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; PILOT STUDY; RISK ASSESSMENT; UNITED STATES;

ADULT; AGED; BLUE CROSS; BLUE SHIELD; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; FEDERAL GOVERNMENT; FEMALE; GOVERNMENT AGENCIES; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH EXPENDITURES; HEALTH SERVICES RESEARCH; HEART FAILURE, CONGESTIVE; HUMANS; INVESTMENTS; MALE; MARYLAND; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PILOT PROJECTS; VIRGINIA;

EID: 30844460102     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.2005.8.346     Document Type: Article

References (28)

1. Robert Wood Johnson Foundation (RWJF). Trends monitoring in chronic care, United States. Princeton, NJ: Robert Wood Johnson Foundation, 1997.
2. American Heart Association. 2001 Heart and stroke statistical update. Dallas, TX: American Heart Association, 2000.
3. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22:6A-13A.
4. Eriksson H. Heart failure: A growing public health problem. J Intern Med 1995;237:135-141.
5. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-712.
6. Ghali JK, Cooper R, Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986: Evidence for increasing population prevalence. Arch Intern Med 1990;150:769-773.
7. Graves EJ. National hospital discharge survey: annual summary, 1993. Vital and Health Statistics Series 13: Data from National Health Survey. Washington, DC: US Government Printing Office, 1995;121:1-63.
8. Centers for Disease Control and Prevention. Cerebrovascular disease mortality and Medicare hospitalization-United States, 1980-1990. MMWR 1992;41:447-480.
9. Simons WR, Haim M, Rizzo J, Zannad F. Effect of improved disease management strategies on hospital length of stay in the treatment of congestive heart failure. Clin Ther 1996;18:726-746.
10. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1994;13:S107-S112.
11. Centers for Disease Control and Prevention. Facts about heart failure in older adults [On-line]. Available: 〈http://www.cdc.gov/od/oc/media/fact/ f990305.htm. 1999〉, accessed December 17, 2002.
12. Knox D, Mischke L. Implementing a congestive heart failure disease management program to decrease length of stay and cost. J Cardiovasc Nurs 1999;14:55-74.
13. DxCG Incorporated. DxCG® risk adjustment software release 3.0. For additional information, see 〈http://www.dxcg.com〉.
14. Drug topics red book. Montvale, NJ: Medical Economics, Inc., 1999.
15. Getzen TE. Medical care price indexes: Theory, construction, and empirical analysis of the U.S. series 1927-1990. Adv Health Econ Health Serv Res 1992;13:83-128.
16. Goetzel RZ, Ozminkowski RJ, Villagra V, Duffy J. Return on investment in disease management: A review. Health Care Fin Rev 2005;26:1-19.
17. Rich MW. Heart failure disease management: A critical review. J Card Fail. 1999;5:64-75.
18. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001;110:378-384.
19. Philbin EF, Rocco TA, Lindenmuth NW, Ulrich K, McCall M, Jenkins PL. The results of a randomized trial of a quality improvement intervention in the care of patients with heart failure. Am J Med 2000;109:501-503.
20. Riegel B, Carlson B, Glaser D, Hoagland P. Which patients with heart failure respond best to multidisciplinary disease management? J Card Fail 2000;6:290-299.
21. Mark DB. Economies of treating heart failure. Am J Cardiol 1997;80:33H-38H.
22. Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med 2001;161:2223-2228.
23. Hershberger RE, Ni H, Nauman DJ, et al. Prospective evaluation of an outpatient heart failure management program. J Cardiac Fail 2001;7:64-74.
24. nd ed. New York: Macmillan, 1986.
25. McCaffrey D, Ridgeway G, Morral A. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods 2004;9:403-25.
26. Weintraub WS, Cole J, Tooley JF. Cost and cost-effectiveness studies in heart failure research. Am Heart J 2001;43:565-576.
27. Moser DK. Heart failure management: Optimal health care delivery programs. Annu Rev Nurs Res 2000;18:91-126.
28. Walker DR, McKinney BK, Cannon-Wagner M, Vance RP. Evaluating disease management programs. Dis Manage Health Outcomes 2002;10:613-619.